Advertisement EY mid banner
Barr Ellison Solicitors – commercial property
ARM Innovation Hub
Advertisement: Wild Knight Vodka
RealVNC mid-banner general
Advertisement: TTP
RealVNC mid banner careers
Advertisement: Bradfield Centre mid
Advertisement: RSM
Advertisement: Cambridge Network
Advertisement: Mogrify
Mid banner advertisement: BDO
10 October, 2019 - 12:02 By Kate Sweeney

No doubting Thomas as Lynch becomes Microbiotica chair

Sanger Institute spin-out Microbiotica, a growing force in microbiome-based therapeutics and biomarkers, has unveiled Thomas Lynch as new non-executive chairman.

Lynch has extensive life sciences and wider board-level experience which will be invaluable in supporting the young Cambridge company’s strategic growth. 

He holds a number of board positions on private and publicly listed life science companies globally. These include: Chairman of Profectus Biosciences, Inc., Adherium Ltd (ASX: ADR), Evofem Biosciences, Inc. (NASDAQ: EVFM) and Amarin Pharmaceuticals (Ireland) Ltd (the principal operating subsidiary of Amarin Corporation plc (NASDAQ: AMRN)); and board member of Stamford Devices Ltd, Aerogen Ltd and GW Pharmaceuticals plc (NASDAQ: GWPH). 

He served on the board of Icon plc (one of the world’s largest clinical research organisations) from 1993 to 2016 and from 2012 to 2016 as its chairman.

Lynch also has significant experience governing hospital and medical charity boards. He is chair of the Ireland East Hospital Group, the Mater Misericordiae University Hospital and the Dublin Academic Medical Centre. 

He is also the chair of Clinical Research Development Ireland (a not-for-profit research partnership between Ireland’s medical schools) and a member of the advisory board of the Institute of Human Virology, University of Maryland, Baltimore.

Lynch said: “The microbiome is rapidly emerging as one of the most exciting areas of biomedicine and one that I believe presents great opportunity. 

“Microbiotica’s world-leading platform positions the company to become a leader in microbiome-based therapeutics and biomarkers as illustrated by its impressive ongoing collaborations with industry, academia and clinicians.”

CEO Mike Romanos added: “Microbiotica’s pipeline of therapeutics and biomarkers, and strategic collaborations such as the multi-year $534 million partnership with Genentech. 

“Tom’s international experience in developing fast-maturing companies will be invaluable to our future ambitions.”

Newsletter Subscription

Stay informed of the latest news and features